Method
Level · gp.fundamentals.debt_to_revenue
Raw value 188.73% · OPTIONAL
· Pharmaceutical Preparations
RESEARCH SNAPSHOTPacira BioSciences, Inc.'s latest supported as-filed period reports revenue of $192.4M. Every value below links to its SEC accession and metric lineage.
No material rule-based research observation currently meets GrossPattern's Insight value threshold. Current state, direction, and filing evidence remain available below.
A multidimensional view of the latest comparable filing—not a composite score or recommendation.
Level · gp.fundamentals.debt_to_revenue
Raw value 188.73% · OPTIONAL
Level · gp.fundamentals.capex_revenue_ratio
Raw value 0.69% · OPTIONAL
Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue
Raw value 29.86% · OPTIONAL
Yoy · gp.fundamentals.revenue
Raw value 6.24% · CORE
Level · gp.fundamentals.inventory_revenue_ratio
Raw value 69.95% · OPTIONAL
Level · gp.fundamentals.gross_margin
Raw value 77.05% · CORE
Business direction, financial quality, capital allocation, and governance evidence remain separate—never collapsed into a recommendation score.
Latest available comparable states within 180 days, normalized with robust median/MAD statistics.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
Cash & equivalents changed -31.5% from the comparable as-filed period.
Debt changed -37.4% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Inventory changed -9.2% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
Each point keeps the date investors could first observe it and its accession.
PCRX · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001628280-26-057759SEC ↗10-QAug 4, 2026Period Jun 30, 20260001628280-26-052635SEC ↗8-KAug 4, 2026Period Aug 4, 20260001628280-26-052527SEC ↗8-KJun 30, 2026Period Jun 28, 20260001628280-26-046136SEC ↗4Jun 12, 2026Period Jun 10, 20260001628280-26-043010SEC ↗4Jun 12, 2026Period Jun 11, 20260001628280-26-043009SEC ↗4Jun 12, 2026Period Jun 10, 20260001628280-26-043008SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
| Filed / transacted | Reporting owner | Semantics | Shares | Price | Notional | Source |
|---|---|---|---|---|---|---|
| Aug 17, 2026Filed Aug 18, 2026 | SLONIN JONATHANChief Medical Officer | Open Market SaleDirect | 3,040 | $23 | $70,619 | Form 4 ↗ |
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Level · gp.fundamentals.operating_margin
Raw value 2.22% · CORE
Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue
Raw value 15.72% · OPTIONAL
Level · gp.fundamentals.sbc_revenue_ratio
Raw value 7.77% · OPTIONAL
Interpretation boundary Direction describes measurable company fundamentals. Governance reports observable evidence only; it does not grade management character or predict stock returns.
Net income changed +196.0% from the comparable as-filed period.
Operating income changed -49.8% from the comparable as-filed period.
Operating margin changed -248 basis points from the comparable as-filed period.
Research & development changed +7.2% from the comparable as-filed period.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001628280-26-043007